Study design.
UC urothelial carcinoma, UC
IV intravenous, Q3W every 3 weeks, UC urothelial carcinoma.Using the dose of BGB-A333 determined in the dose-escalation phase (1350 mg), and the standard dose of tislelizumab that has been established previously [Following the determination of the RP2D as 1350 mg, Phase 2 (combination dose expansion) evaluated the anti-tumour activity, safety and tolerability of BGB-A333 in combination with tislelizumab. Phase 2 (combination dose expansion) enroled patients with UC only, chosen based on data from Phase 1a.